← GPCalc

NICE Lipid Calculator

Adults · NICE NG238 CVD risk assessment and reduction, including lipid modification (Dec 2023; latest change Oct 2025) · with TA385, TA393/394, TA694, TA733, TA805 and CG71

Scenario

Patient

Cardiovascular disease

Other risk conditions

Lipid profile (mmol/L)

Non-HDL and LDL will be calculated here.

QRISK3 10-year risk calculator

Optional. Calculates the 10-year risk of heart attack or stroke and fills in the QRISK3 box above. Uses the age, sex, diabetes, eGFR and cholesterol entered in this form. For adults aged 25–84 without established CVD.

Enter QRISK3 details

SBP variability = standard deviation of at least two recent systolic readings; leave blank if unknown (an average value is assumed). Townsend deprivation score from the postcode; leave blank for 0 (about average).

Current lipid-lowering treatment

Before escalating

Safety bloods & symptoms

Secondary causes

Tick any present. Treat these before or alongside lipid-lowering treatment, and before any specialist referral.

FH assessment – Dutch Lipid Clinic Network

Use the untreated LDL. Only the highest score in each group counts.

Family history
Personal history
Examination & DNA

DLCN score: –

NICE-recommended plan

Enter age to see the plan.

Decision support only, based on NICE NG238, linked technology appraisals and CG71. It does not replace clinical judgement, the full guidance, the SPC or local formularies (PCSK9 inhibitors and some therapies may be specialist-initiated locally). Lipid targets and statin choices for people with FH are managed under CG71.

Quick reference

Who to treat
GroupNICE
Established CVDOffer atorvastatin 80 mg (lower if interactions, adverse-effect risk or preference) (1.7.2–1.7.3)
CKD (eGFR <60 and/or albuminuria)Offer atorvastatin 20 mg, primary or secondary prevention (1.8.1)
QRISK3 ≥10% (ages 25–84, incl. T2DM)Offer atorvastatin 20 mg after lifestyle discussion (1.6.7)
QRISK3 <10%Don't rule out atorvastatin 20 mg if the person prefers a statin or risk may be underestimated (1.6.8)
Aged 85+Consider atorvastatin 20 mg (1.6.9)
Type 1 diabetesOffer if >40, diabetes >10 yrs, nephropathy or other risk factors; consider for others aged 18–40. Atorvastatin 20 mg (1.6.10–1.6.12)
FHHigh-intensity statin, aim >50% LDL reduction; specialist care (CG71)

Don't use QRISK3 for T1DM, CKD (eGFR <60 and/or albuminuria) or FH – treat as high risk (1.1.9).

Targets & monitoring
GroupTarget
Primary prevention (incl. CKD, T1DM)>40% reduction in non-HDL (1.6.1, 1.8.2)
Secondary preventionLDL ≤2.0 or non-HDL ≤2.6 mmol/L (1.7.1)
FH>50% LDL reduction from baseline (CG71)

Lipids + LFTs at 2–3 months after starting or changing treatment; LFTs at 12 months, then only if clinically indicated (1.11.1–1.11.2). CK only if muscle symptoms (1.11.3–1.11.5). Annual review; annual lipids in secondary prevention, consider in primary (1.11.8–1.11.10).

Statin intensity
StatinLow (20–30%)Medium (31–40%)High (>40%)
Atorvastatin–10 mg20, 40, 80 mg
Rosuvastatin–5 mg10, 20, 40 mg
Simvastatin10 mg20, 40 mg80 mg*
Pravastatin10, 20, 40 mg––
Fluvastatin20, 40 mg80 mg–

*Simvastatin 80 mg not recommended (muscle toxicity). Intolerant of atorvastatin → try rosuvastatin (same intensity group) (1.9.2).

Referral thresholds
  • TC >9.0 or non-HDL >7.5 mmol/L → specialist assessment, even without family history (1.4.5)
  • TG >20 mmol/L (not due to alcohol or poor glycaemic control) → urgent specialist review (1.4.6)
  • TG 10–20 → repeat fasting in 5 days to 2 weeks, review secondary causes; seek advice if still >10 (1.4.7)
  • TG 4.5–9.9 → risk may be underestimated; seek advice if non-HDL >7.5 (1.4.8)
  • FH: Simon Broome possible/definite or DLCN >5 → FH specialist service for DNA testing (CG71 1.1.6)
  • Possible homozygous FH: LDL >13 mmol/L → specialist centre (CG71 1.1.8)
Add-on therapies (TA criteria)
DrugNICE criteria
Ezetimibe (TA385)With statin if not controlled on optimised statin; alone if statin contraindicated or not tolerated. Secondary prevention: consider even if target met (1.7.10)
Bempedoic acid + ezetimibe (TA694)Statins contraindicated/not tolerated and ezetimibe alone doesn't control LDL
Inclisiran (TA733)History of ACS, revascularisation, CHD, ischaemic stroke or PAD and LDL persistently ≥2.6 despite maximum tolerated lipid-lowering therapy
Alirocumab / evolocumab (TA393/394)Non-FH: CVD high risk LDL >4.0; very high risk LDL >3.5; no CVD – not recommended. HeFH: no CVD LDL >5.0; with CVD LDL >3.5. LDL persistently above threshold despite max tolerated therapy
Icosapent ethyl (TA805)Established CVD, on statin, fasting TG ≥1.7 and LDL >1.04 and ≤2.60 mmol/L

High-risk CVD = ACS, revascularisation, CHD, ischaemic stroke, PAD. Very high risk = recurrent events or polyvascular disease.

Simon Broome & DLCN

Simon Broome (adults): TC >7.5 or LDL >4.9 mmol/L, plus

  • Definite FH: tendon xanthomas in patient or 1st/2nd-degree relative, or DNA evidence
  • Possible FH: family history of MI <50 in 2nd-degree or <60 in 1st-degree relative, or TC >7.5 in adult 1st/2nd-degree relative (or >6.7 in child/sibling <16)

DLCN LDL points: ≥8.5 = 8; 6.5–8.4 = 5; 5.0–6.4 = 3; 4.0–4.9 = 1.
Score: >8 definite, 6–8 probable, 3–5 possible, <3 unlikely. Refer if >5.

Lifestyle advice & patient leaflet
  • Cardioprotective diet: total fat ≤30% of energy, saturated fat ≤7%; replace saturated with mono- and polyunsaturated fats; wholegrains, fruit, vegetables, fish (1.3)
  • Physical activity, weight management, alcohol within limits, stop smoking (1.3)
  • Don't advise plant stanols or sterols to prevent CVD (1.3.12)
  • Don't routinely offer aspirin for primary prevention (1.2.1)